leadf
logo-loader
RNS
viewSynairgen PLC

Synairgen plc - Annual Report and Notice of Annual General Meeting

RNS Number : 8703O
Synairgen plc
03 June 2020
 

Press release

Synairgen plc

('Synairgen' or the 'Company')

 

 Posting of Annual Report and Accounts and Notice of Annual General Meeting

 

 

Southampton, UK - 3 June 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that the Annual Report and Financial Statements for the year ended 31 December 2019 and Notice of Annual General Meeting was posted to shareholders today and are available on the Company's website at www.synairgen.com.

 

 

Annual General Meeting

In line with the UK Government's latest guidelines on COVID-19, Synairgen will host its AGM as a closed meeting at The Blueprint Design Company Limited, Martins Barn, Birdham Road, Chichester, West Sussex PO20 7BX at 9.00 a.m. on 29 June 2020. The health and safety of the Company's shareholders as well as its employees is of paramount importance and, as a result, it will not be possible for shareholders to attend the meeting in person. Any shareholders attempting to attend the AGM will be refused entry.

 

The Annual General Meeting Notice was posted to shareholders today and is available on the Company's website at www.synairgen.com. The AGM will be convened with the minimum necessary quorum of two shareholders. The outcome of the resolutions will be determined by shareholder vote based on the proxy votes received. Shareholders are therefore strongly encouraged to vote by proxy on the resolutions contained in the AGM notice. Given the restrictions on attendance, shareholders are also strongly encouraged to appoint the "Chairman of the Meeting" as their proxy rather than another person who will not be permitted to attend the meeting. To ensure votes are counted at the AGM, completed proxy forms should either be completed electronically (using either Link Asset Services' Signal Shares share portal service at www.signalshares.com or if you hold shares in uncertificated form (i.e. in CREST) by completing a CREST Proxy Instruction) or be posted to: Link Asset Services, PXS 1, 34 Beckenham Road, Beckenham, Kent BR3 4ZF and must be received by 9.00 a.m. on 25 June 2020 in order to be valid. This is particularly important given that COVID-19 has caused delays to the collection and delivery of postal services.

 

The results of the AGM will be announced to the London Stock Exchange and placed on the Company's website, in the usual way, as soon as practicable after the conclusion of the AGM.

 

The Board would like to take this opportunity to thank all shareholders for their continued support and understanding in these exceptional circumstances and wish them well during this time.

 

- End -

 

 

 

 

For further enquiries, please contact:

 

Synairgen plc

Richard Marsden, Chief Executive Officer

John Ward, Finance Director

Tel: + 44 (0) 23 8051 2800

 

finnCap

Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)

Alice Lane, Manasa Patil (ECM)

Tel: + 44 (0) 20 7220 0500

 

Consilium Strategic Communications (Financial Media and Investor

Relations)

Mary-Jane Elliott, Sue Stuart, Olivia Manser

synairgen@consilium-comms.com

Tel: +44 (0) 20 3709 5700

 

Notes for Editors

 

About Synairgen 

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.  

 

Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ACSSSUFIDESSEFM

Quick facts: Synairgen PLC

Price: 165

Market: AIM
Market Cap: £246.57 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Synairgen PLC pleased with further positive data from lead COPD drug

Richard Marsden, chief executive of Synairgen plc (LON:SYN), tells Proactive's Andrew Scott data from the ongoing phase II study of their SNG001 drug suggests it's having the desired effect in boosting the antiviral defences of chronic obstructive pulmonary disease (COPD)...

on 28/6/18